Posts Tagged ‘Clickotine’
Click Therapeutics raises further $52M to build up digital therapeutics pipeline for depression, insomnia, smoking cessation and more
With Sanofi still on board, Click Therapeutics closes $52M series B for digital therapeutics in depression, chronic pain and more (Fierce Biotech): Another medtech developer’s plans to create digital therapeutics to treat a wide range of illnesses are clicking into place, thanks to a third multimillion-dollar investment in Click Therapeutics in barely a year.
Read MoreClick Therapeutics raises $30 million in debt to advance commercialization of smoking cessation app Clickotine
Click Therapeutics Secures $30M in Growth Capital from K2 HealthVentures to Expand Operations (press release): Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today announced $30 million in debt financing from K2 HealthVentures (K2HV), a healthcare-focused specialty finance company, to accelerate commercialization of its leading smoking cessation solution, Clickotine™,…
Read MoreSanofi Ventures leads $17M investment in Click Therapeutics, finalist @ 2017 Brainnovations Pitch Contest
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum (Xconomy): “Drug makers are making more bets on the nascent field of digital medicine. The latest example: Click Therapeutics announced Monday that it grabbed a $17 million investment led by Sanofi Ventures, the Cambridge, MA-based venture capital arm of the French pharmaceutical giant.
Read More